Full Press Release Details
Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
phospholipid ether (PLE) molecules ability to target wide range of tumors
N.J., October 15, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced Jarrod
Longcor, chief business officer of Cellectar, presented a poster at the Cancer Research UK-AACR Joint Conference on Engineering
and Physical Sciences in Oncology, being held from October 15 - 17, 2019 in London, United Kingdom.
The poster, entitled:
"Phospholipid ether delivery vehicle shows specificity for a broad range of tumor cells and provides a novel and improved
approach for targeted therapy," featured data demonstrating that phospholipid ether drug conjugates (PDCs) were capable
of delivering small molecule cytotoxins selectively to tumor cells and were well tolerated in animal models. In the data presented,
all animals exposed to a single infusion of the payload alone died, while all animals receiving multiple doses with the PDCs survived
with no adverse effects observed at all dose levels tested. Additionally, PDCs showed rapid uptake and release of 20% to 40% of
the conjugate and payload in a wide range of tumor cells. The PDCs also demonstrated potent activity against the tumor cells with
inhibitory concentrations in the low nanomolar range.
an exciting novel class of targeted oncology agents with a unique method of action that offers an attractive alternative to antibody
drug conjugates," said Jarrod Longcor, chief business officer of Cellectar. "The ability to deliver up to 40% of the
PDCs to the tumor versus less than 1% for antibody drug conjugates means that some payloads that previously could not be delivered
to tumor cells in high enough amounts may now be delivered at levels that could result in activity. Additionally, the demonstration
of activity and tolerability is a major milestone in the development of our PDC programs."
Cellectar's product candidates are built
upon a patented delivery and retention platform that utilizes optimized phospholipid ether-drug conjugates (PDCs ) to target
cancer cells. The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and cancer stem cells, including
hematologic cancers and solid tumors. This selective delivery allows the payloads' therapeutic window to be modified, which
may maintain or enhance drug potency while reducing the number and severity of adverse events. This platform takes advantage of
a metabolic pathway utilized by all tumor cell types in all cell cycle stages. Compared with other targeted delivery platforms,
the PDC platform's mechanism of entry does not rely upon specific cell surface epitopes or antigens. In addition, PDCs can
be conjugated to molecules in numerous ways, thereby increasing the types of molecules selectively delivered. Cellectar believes
the PDC platform holds potential for the discovery and development of the next generation of cancer-targeting agents.
Cellectar Biosciences
is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing
proprietary drugs independently and through research and development (R&D) collaborations. The company's core objective
is to leverage its proprietary Phospholipid Drug ConjugateTM (PDC) delivery platform to develop PDCs that specifically
target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's
PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and
it plans to develop PDCs independently and through research and development collaborations.
lead PDC therapeutic, CLR 131, is currently in three clinical studies - a Phase 2 study, and two Phase 1 studies. The Phase
2 clinical study (CLOVER-1) is in relapsed/refractory (R/R) B-cell malignancies, including multiple myeloma (MM), chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma
(MCL), and diffuse large B-cell lymphoma (DLBCL). The company is also conducting a Phase 1 dose escalation study in patients with
R/R multiple myeloma (MM) and a Phase 1 study in pediatric solid tumors and lymphoma.
product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900) and several partnered PDC assets.
For more information,
please visit www.cellectar.com or join the conversation by liking and following us on
our social media channels: Twitter, LinkedIn, and Facebook.
Forward-Looking Statement Disclaimer
contains forward-looking statements. You can identify these statements by our use of words such as "may", "expect",
"believe", "anticipate", "intend", "could", "estimate", "continue",
"plans", or their negatives or cognates. These statements are only estimates and predictions and are subject to known
and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements
made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development
involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related
to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of CLR 131, the
ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development
thereof, the completion of clinical trials, the FDA review process and other government regulation, the volatile market for priority
review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition
from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form
10-K for the year ended December 31, 2018 and Form 10-Q for the quarters ended March 31, 2019 and June 30, 2019. These forward-looking
statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.